Introduction
============

Cervical cancer is the fourth most common cancer among women worldwide in terms of morbidity and mortality. More than 85% of cervical cancers occur in the developing countries.[@B1] China accounts for 14% of the world\'s annual incidence of cervical cancer, and hence it remains an important public health problem in China. [@B2], [@B3] The incidence of cervical cancer in Shanxi Province, China is strikingly high.[@B4] Persistent infection of high-risk Human Papillomavirus (hrHPV) infection is critical for the development of almost all cervical cancers and precancerous lesions.[@B5] A meta-analysis of 48 studies showed that HPV16 and HPV18 are the most prevalent genotypes worldwide.[@B6] It has been shown that the distribution of HPV genotypes in cervical cancers varies by countries and regions.[@B7] China is a large country with varied socioeconomic conditions among different regions, and HPV infections differ accordingly.[@B8] A large study from China, which included 51,345 women, has demonstrated three most common hrHPV types were HPV52, 16, and 58, while HPV18 was only the 6^th^most common type.[@B9]

HPV vaccination is one of the most important measures to prevent HPV infection.[@B10] However, all currently available vaccines were developed based on the epidemiological data from Western countries, and as a result, target HPV16, HPV18 and several other commonly identified subtypes in Western countries.[@B11], [@B12], [@B13] Implementation of these vaccines in China may not be able to achieve the desired preventive efficacy. Therefore, in order to develop HPV vaccines specific for Chinese women, it is necessary to investigate HPV genotype distributions in China.

Materials and Methods
=====================

Study participants
------------------

The cases with histological diagnosis of CIN2/3 rendered between August 2011 and August 2016 were retrospectively searched in the patient information system at Second Hospital of Shanxi Medical University (SHSMU). Only the cases with prior HPV genotyping results in the preceding 6 months were included in the study and analyzed. Other clinical information, including age and clinical history were also collected. Histopathologic diagnoses were reported on samples including endocervical curettage specimens, cervical biopsies, loop electrosurgical excision procedures or cold-knife conization. The Second Hospital of Shanxi Medical University is a large, integrated, public health system located in the capital of Shanxi, which accommodates patients from all over Shanxi province.

HPV Geno-array test
-------------------

HPV detection and genotyping was tested using HybriMax HPV Geno-Array kit (Hybribio Biotechnology Limited Corp., Chaozhou, China) at the Second Hospital of Shanxi Medical University laboratory. The HPV Geno-Array can determine 21 HPV types, including 15 hrHPV types(16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, and 68) and 6 low risk HPV (lrHPV) types (6, 11, 41, 42, 44, and CP8304).Test was performed according to the manufacturer\'s instructions. [@B14] Briefly, PCR was performed in a 25 μL reaction mixture containing 5 μL extracted DNA*,* 0.75 μL DNA Taq polymerase and 19.25 μL PCR-mix solution containing MY09/11 primer system. The PCR protocol was: denaturing at 95 °C for 9 min, followed by 40 cycles of 20s at 95 °C, 30s at 55 °C, and 30s at 72 °C, at last a finally extension at 72 °C for 5 min. A positive control and a negative control were run in each PCR analysis process to control for possible contamination and accuracy. The kit can simultaneously identify 21 HPV genotypes: adding NBT/BCIP solution to display the results, a positive result was indicated by a clearly visible indigo dot. The HPV-genotype result was determined by the position of the HPV-genotype probes on the microarray chip. The kit can simultaneously identify 21 HPV genotypes: adding NBT/BCIP solution to display the results, a positive result was indicated by a clearly visible indigo dot. The HPV-genotype result was determined by the position of the HPV-genotype probes on the microarray chip. Multiple dots indicated multiple infections. [@B15]

Colposcopy and cervical histopathologic diagnosis
-------------------------------------------------

Colposcopy exams were performed by specialists according to a standardized protocol. During the exam, all visually abnormal areas were biopsied. The squamocolumnar junction was biopsied ("random biopsy") if no visible lesion identified. Endocervical curettage (ECC) was then performed according to the aforementioned indications.

Statistical analysis
--------------------

The Pearson chi-square test was used for statistical analysis, which was conducted with SAS 9.1 software (SAS Institute, Cary, North Carolina). A P value less than. 05 was considered statistically significant.

Results
=======

Overall HPV prevalence
----------------------

A total of 1,387 CIN2/3 cases with HPV genotyping results within 6 months prior to histological diagnosis were included in the study. The overall hrHPV positive rate was 91.9% (1274/1387). The average time period from HPV testing to histological diagnosis was 0.4 months (range: 0.1-6 months) and the average age was 45.7 years (range: 21-83 years).

Distribution of single and multiple hrHPV infections
----------------------------------------------------

Single hrHPV infection was identified in 65.0% of all women (902/1,387), accounting for 71.0% (902/1,271) of hrHPV positive cases. Infection with multiple hrHPV types was identified in 26.6% of all women, accounting for 29.0% of hrHPV positive cases. Among the women infected with multiple hrHPV types, infection of two genotypes was most commonly observed with an overall prevalence rate of 17.5%. Infection with three and more hrHPV types were found in 99 women with an overall prevalence rate of 7.1% (Table [1](#T1){ref-type="table"}).

HrHPV genotype distribution
---------------------------

The most commonly detected hrHPV genotype was HPV16 (59.3%), followed by HPV58 (14.4%) and HPV33 (10.0%), while HPV18 was in the 6^th^ position (6.0%) (Table [2](#T2){ref-type="table"}).

HrHPV infection among women of different Ages
---------------------------------------------

All the 1,387 cases were divided into three age groups (\<40 years, 40-49 years, and ≥50 years). The overall prevalence of hrHPV was 93.2% in women\<40 years, 90.0% in women 40-49 years, and 92.2% in women ≥50 years. HrHPV positive rates showed no significant difference among these three age groups (p=0.1978). Additionally, the positive rates of HPV16 in the three groups were also similar and were 59.2% in women \<40 years, 58.2% in women 40-49 years, and 60.6% in women ≥50 years respectively (p=0.7273).

Discussion
==========

Epidemiological studies have suggested a substantial difference in the prevalence and genotype distribution of hrHPV infection among women from different countries. [@B16],[@B17],[@B18],[@B19],[@B20] Several large studies from China have demonstrated hrHPV prevalence rates in general population range from 9.9% to 21.1%. [@B9], [@B21], [@B22] However, studies of hrHPV infection in Chinese women with CIN2/3 were lacking. A study has reported that approximately 82.4% of cervical precancerous lesions and 92% of cervical invasive carcinoma are HPV-positive[@B23]. Zhao et al. reported that all 12 cases of cervical cancer and 31 cases of CIN3, and 95.3% of CIN2 (43 cases) were hrHPV positive.[@B24] To our knowledge, the current study is one of the largest studies to investigate hrHPV prevalence in Chinese women with CIN2/3, demonstrating that 91.6% of these women were hrHPV positive.

In consistent with previous reports,[@B25], [@B26] single HPV type infection is the most common infection in the current study, followed by the HPV infection with two types. Infection with 3 or more HPV types is rare. It remains exclusive whether HPV infection with multiple types is linked to occurrence or progression of cervical cancerous/precancerous lesions. One study suggested HPV infection with multiple types has increased risk for cervical cancerous/precancerous lesions[@B27], while other studies did not show any increased risk for HPV infection with multiple types. [@B28], [@B29] Further studies are still warranted to elucidate the role of infection with multiple HPV types in the development of cervical cancer.

HPV genotyping results for Chinese women with CIN2/3 are limited. The current study demonstrated the most commonly detected hrHPV genotype was HPV16 (59.3%), followed by HPV58 (14.4%) and HPV33 (10.0%), while HPV18 was only in the 6th position (6.0%). HPV16 was the predominant type among women with CIN2/3 in this study, consistent with previous studies from Western countries. [@B30],[@B31] However, the 2^nd^ and 3^rd^ most commonly detected types in current study were HPV58 and HPV33, which are different from the results observed in women from Western countries.^32,\ 33,\ 34,\ 35^HPV 16, HPV 33, and HPV 52 have been reported to be the most prevalent HPV types in Chinese women, however, the distribution of HPV genotype has been shown to be different from regions to regions in China.^9,\ 36,\ 37,\ 38^A study of 6723 subjects in four large cities (Beijing, Shanghai, Shenzhen, and Shenyang) and four rural areas (Shanxi: Xiangyuan, Yangcheng, Henan Xinmi, and Xinjiang: Hotan) in China demonstrated HPV16 is the most common type, followed by HPV58 and HPV18. [@B39] However, all these results were derived from general Chinese population, none of the studies specifically investigated hrHPV genotyping in women with cervical precancerous/cancerous lesions. Our current study is the one of the largest to investigate hrHPV genotype distribution among women with CIN2/3, showing the top three most common types were HPV16 (59.3%), HPV58 (14.4%) and HPV33 (10.0%), while HPV18 was in the 6^th^ position (6.0%). A recent study indicated that the prevalence of HPV58 was 22.1% and 21.1% among HIV-1 positive women with CIN2 in Burkina Faso and South Africa respectively, and 23.1% and 15.1% among women with CIN3 and above lesions.[@B40]

In China, the development and application of HPV vaccines still face many challenges. Our study demonstrated that, even though HPV16 was the predominant type of HPV among Chinese women with CIN2/3, the following most common HPV types were not exactly the same as those found in other countries or regions. These data may provide a basis for formulating cervical cancer prevention strategies in China.

On April 24, 2014, the US Food and Drug Administration (FDA) approved a proposal by Roche Molecular Systems, (HPV) test as an alternate primary cervical cancer screening method for women aged 25 to 65 years. Current study showed 8% CIN2/3 patients had a negative HPV testing result before the histological diagnosis of high grade dysplasia, indicating the limitation of HPV testing as primary cervical cancer screening.

In summary, current study is the one of the largest case studies of HPV genotyping in Chinese women with histological diagnosis of CIN2/3. The knowledge of variable hrHPV genotypes in different countries and regiones may be important for the development and application of HPV vaccines.
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###### 

1387 cases with genotyping results 6 months before CIN2/3 diagnosis

  HPV infection                     Positive Case   \%
  --------------------------------- --------------- ------
  1 HrHPV only                      902             65.0
  2 HrHPV only                      244             17.5
  ≥3 HrHPV only                     96              6.9
  Any mixed Hr and LrHPV            32              2.3
  LrHPV only                        10              0.7
  Negative (no both Hr and Lr HPV   103             7.4
  Total                             1387            100%

Abbreviations: HrHPV, high-risk human papillomavirus; LrHPV, low-risk human papillomavirus number; CIN2/3, cervical intraepithelial neoplasia 2/3.

###### 

HPV genotypes screening test results 6 months before CIN2/3 diagnosis (1387 cases)

  HPV type   Case No   Percentage
  ---------- --------- ------------
  HrHPV                
  16         823       59.3
  18         79        6.00
  31         105       7.6
  33         139       10.0
  35         31        2.2
  39         47        3.4
  45         25        1.8
  51         67        4.8
  52         98        7.1
  53         60        4.3
  56         35        2.5
  58         200       14.4
  59         27        1.9
  66         22        1.6
  68         0         0.00
  LrHPV                
  11         23        1.7
  42         12        0.9
  81         14        1.0
  6          7         0.5
  41         3         0.2
  44         4         0.3

Abbreviations: HrHPV, high-risk human papillomavirus; LrHPV, low-risk human papillomavirus number; CIN2/3, cervical intraepithelial neoplasia 2/3.No, number.
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